TrialOphthalmic research2023

A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin.

Colin J Vize et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.